OncoMatch/Clinical Trials/NCT06667076
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Is NCT06667076 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Amivantamab and Lazertinib for carcinoma, non-small-cell lung.
Treatment: Amivantamab · Lazertinib · Chemotherapy: Pemetrexed · Chemotherapy: Carboplatin — The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR exon 19 deletion
Required: EGFR l858r
Disease stage
Metastatic disease required
advanced or metastatic non-small cell lung cancer (NSCLC) that is not amenable to curative intent therapy; at least 1 measurable lesion, according to RECIST version (v)1.1, that has not been previously irradiated
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Southern Cancer Center, PC · Daphne, Alabama
- Clearview Cancer Institute · Huntsville, Alabama
- City of Hope Phoenix · Goodyear, Arizona
- The Oncology Institute of Hope and Innovation · Cerritos, California
- City of Hope Corona · Corona, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify